[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-biomarkers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-biomarkers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634019","hepatoprotective-effects-of-reishi-mushroom--ganoderma-lucidum-among-metabolic-dysfunction-associated-fatty-liver-disease-patients-100634019",false,"NCT07534241","Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients","Inclusion Criteria:\n\n* Adults aged 35-65 years\n* BMI between 18.5 and 30 kg\u002Fm².\n* Complete Blood Count test ranges, WBC \\\u003C 4,000-11,000 cells\u002FµL, RBC Men \\\u003C 4.5-6.0 \u002F Women 4.0-5.5 million\u002FµL, Hemoglobin: Men \\\u003C 13.5-17.5 \u002F Women 12.0-15.5 g\u002FdL, Platelets \\\u003C 150,000-450,000 cells\u002FµL.\n* Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg\u002FdL high 200-499mg\u002FdL and 500 mg\u002FdL are above high.\n* Liver function test markers, ALT \\> 56 U\u002FL, AST\\>40 U\u002FL, ALP\\>147 UL.\n* Inflammatory markers: CRP \\>3 mg\u002FL, - IL-6 ≥3 pg\u002FmL, TNF-α ≥8 pg\u002FmL.\n* Elevated blood sugar levels, or hyperglycemia, refer to a typically above 126 mg\u002FdL, fasting or 200 mg\u002FdL post-meal.\n\nExclusion Criteria:\n\n* ● Diagnosed with severe cardiovascular disease, liver failure, or renal impairment.\n\n  * Pregnant or lactating women.\n  * Individuals currently on statins, ezetimibe, PCSK9 inhibitors, or any other lipid-lowering therapy.\n  * Allergic to mushrooms.\n  * Diagnosed with celiac disease or other chronic gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis).\n  * History of malignancy.\n  * Participation in another clinical trial within the last 3 months.",true,"ALL","35 Years","65 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress.\n\nFindings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in",[27,28],"Lipid Profile","Liver Biomarkers","RECRUITING","2026-04-09",{"date":32,"type":33},"2026-04-16","ACTUAL",{"date":35,"type":33},"2025-10-02",{"date":37,"type":21},"2026-04-15",{"name":39,"class":40},"University of Lahore","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100616033","liver-affection-in-pregnant-women-at-sohag-university-hospital-100616033","NCT07300345","Liver Affection in Pregnant Women at Sohag University Hospital","Liver Affection in Pregnant Women at Sohag University Hospitals","LAIPWASUH","Inclusion Criteria:\n\nAll pregnant women \\>18 years old with elevated Liver enzyme levels All pregnant women \\>18 years old with elevated bilirubin level\n\nExclusion Criteria:\n\nPregnant women who refuse to participate in the study, Pregnant women with biliary diseases (e.g., cholangitis, cholecystitis)\n\n\\-","FEMALE","18 Years","50 Years",{"count":54,"type":21},80,"OBSERVATIONAL","This study investigates the prevalence, causes, and clinical outcomes of liver disorders among pregnant women attending Sohag University Hospital. It aims to identify the most common hepatic conditions occurring during pregnancy, evaluate their impact on maternal and fetal health, and assess the effectiveness of current diagnostic and management approaches. By analyzing clinical data, laboratory findings, and pregnancy outcomes, the study highlights the importance of early detection and proper management of liver diseases to reduce associated complications and improve overall maternal-fetal prognosis.",[28],"NOT_YET_RECRUITING","2025-12-09",{"date":61,"type":33},"2025-12-23",{"date":63,"type":21},"2025-12-15",{"date":65,"type":21},"2026-12-20",{"name":67,"class":40},"Eman Ashraf Saad Ahmed"]